99578-85-5Relevant academic research and scientific papers
CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS
-
Paragraph 0344; 0345; 0369; 0370, (2022/03/31)
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.
Vinyl-Stilbene Compounds and Uses Thereof
-
Paragraph 0255; 0267-0273, (2021/06/22)
The present invention relates to a biphenyl - stilbene (Vinyl-stilbene) - based compound and a pharmaceutical composition for preventing or treating norovirus infection comprising the same as an active ingredient. The present invention can be usefully used as a pharmaceutical composition for treating norovirus infection by showing superior norovirus inhibitory activity and lower cell toxicity as compared to previously known compounds.
MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS
-
Page/Page column 61, (2008/06/13)
Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.
Trifluoromethybenzylphosphonates useful in treating osteoporosis
-
, (2008/06/13)
Novel benzylphosphonate compounds of the general formula I: STR1 are disclosed as useful in treating bone wasting diseases including postmenopausal osteoporosis in increasing in mammals bone formation and bone mass.
Trifluoromethylbenzylphosphonates useful in treating osteoporosis
-
, (2008/06/13)
Novel benzylphosphonate compounds of the general formula I: STR1 are disclosed as useful in treating bone wasting diseases including postmenopausal osteoporosis in increasing in mammals bone formation and bone mass.
